7:10 am Morning Check-In: Served with coffee + light breakfast
8:10 am Chair’s Opening Remarks
8:15 am Keynote: Shaping The Future of Skin Therapeutics: Clinical Momentum & Strategic Innovation
Synopsis
- Evaluating progress in dermatological therapies by reviewing approved products and late-stage clinical assets in conditions like acne, atopic dermatitis, and psoriasis
- Exploring market potential in underserved segments of dermatology, including paediatric patients, rare inflammatory diseases, and post-biologic maintenance strategies
- Evaluating tools with the most promise for the future: from AI, synthetic biology platforms, and scalable topical manufacturing to unlock next-gen innovations
Pioneering The Next Generation Of Dermatology Innovation Through Mechanistic Precision, Digital Disruption & Deeper Disease Understanding
8:45 am SCARLETRED AI for Next-Gen Dermatology Research: Blending Human Intuition with Machine Learning Precision
Synopsis
- Standardized, high-resolution mobile imaging for consistent and scalable data capture across clinical sites
- Smart Image analysis powered by objective data and machine learning in Psoriasis, Hidradenitis Suppurativa, and other inflammatory skin diseases
- Real-time AI-driven decision support tools to enhance clinical trial design and execution
- Development of digital biomarkers and novel endpoints to accelerate treatment validation in clinical R&D and post-marketing studies
9:00 am Advancing Precision Depigmentation Through Real-World Learnings in Vitiligo
Synopsis
- Key outcomes and safety insights from adult and adolescent trials investigating topical JAK inhibition in vitiligo
- Translating clinical success to pediatric populations and adapting protocols for less extensive disease
- Navigating operational and regulatory challenges including enrollment barriers and long-term data expectations
- Applying lessons from atopic dermatitis programs to improve trial design, endpoint strategy, and FDA alignment in vitiligo
9:00 am Speed Networking
Synopsis
A prime chance to make the most of in-person networking, and forge new connections as new companies enter and existing ones broaden their presence within the dermatology space.
Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.
10:00 am Morning Break & Refreshments
10:35 am Modulating Microbial Behaviors to Treat Skin Disease: ENS-002 in Atopic Dermatitis & 33 Million Data Points for Targeted Microbial Interventions
Synopsis
- Discover how Concerto’s kChip platform identified ENS‑002 by screening over 5 million microbial combinations
- Highlight the Phase I trial testing ENS‑002’s safety and impact on Staphylococcus aureus in AD patients
- Explore how microbe-based therapies like ENS‑002 can provide long-term relief without the risks of immunosuppression
- Preview the Skin Universe Project’s role in enabling future microbial consortia for other dermatologic conditions
Advancing Precision Dermatology Through Multi-Omic Profiling, Digital Imaging, And Microbiome-Driven Therapies
11:05 am Novel Imaging Endpoints: Redefining Objectivity in Dermatology Clinical Trials
Synopsis
- Automatic detection and segmentation of vitiligo
- 3D photography as a way to quantify dermatologic conditions
- Artificial Intelligence: automatic scoring of acne severity
11:20 am Targeting Durable Repigmentation through Tissue‑Resident Immune Control in Vitiligo
Synopsis
- Resident memory CD8⁺ T cells persist in vitiligo lesions and drive relapse even after repigmentation with JAK inhibitors
- IFN‑γ signaling via JAK pathways mediates depigmentation yet inhibition does not deplete Trm cells, limiting treatment durability
- Blocking IL‑15 signaling shows promise in mouse models to eliminate Trm and achieve sustained repigmentation beyond temporary response
- Emerging clinical strategies focus on combining pathway-targeted agents with durable endpoints and relapse-prevention frameworks
11:50 am Session Reserved for Legit.Health
12:00 pm Designing Smarter Trials for Chronic Inflammatory Skin Diseases
Synopsis
- Translating Dermatologic Complexity into Clinical Trial Clarity: Explore how nuanced disease characteristics – like fluctuating severity, lesion variability, and patientreported outcomes – can be strategically integrated into trial design for chronic inflammatory skin conditions
- From Proof-of-Concept to Approval: Learn how to optimize early-phase and confirmatory trial designs, including placebo use, blinding strategies, and endpoint selection, to meet regulatory expectations and accelerate development timelines
- Patient-Centric and Program-Smart: Discover how thoughtful patient selection, long-term safety planning, and real-world considerations (e.g., combination therapies, relapse tracking) can enhance trial relevance and commercial success
Charting The Future Of Dermatology R&D: Emerging Science, Novel Modalities & Translational Breakthroughs In Inflammatory Skin Disease
1:00 pm Roundtable Discussion: How Can Patient-Derived Cells and High- Throughput Models Advance Our Understanding of Skin Disease Heterogeneity?
Synopsis
- Exploring the use of patient-derived cells to better model individual variability driven by genetics, microenvironment, and environmental triggers
- Using simple cell-based assays to screen therapeutic candidates before moving into more complex, tissue-like co-culture systems
- Investigating how inflammatory cytokines and molecular signals can be layered into co-cultures to mimic lesion-specific disease states
- Understanding the importance of recapitulating 3D skin architecture to accurately predict treatment efficacy in heterogeneous patient populations
1:30 pm Session Reserved for Canfield Scientific
2:30 pm Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in dermatology therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations.
Precision Immunomodulation, Targeted Innovation & Rethinking Route Of Delivery For The Next Generation Of Skin Therapies
3:00 pm Afternoon Break & Refreshments
3:00 pm Harnessing Immunomodulation to Transform Atopic Dermatitis & Beyond
Synopsis
- Immune mediation may result in complex dermatologic pathologies
- Immunomodulating, specifically focusing on T cells, may positively contribute to disease management
- Targeting the OX40 pathway in dermatology, eg atopic dermatitis, may result in sustained changes, representing remission (with case studies)
- Designing biologics with extended dosing intervals and low immunogenicity to reduce treatment burden and improve adherence
- Translational strategies are able to bridge mechanistic understanding to clinic-ready molecules that balance potency, safety, and patient convenience
4:00 pm Leveraging Genetically Guided Antibody Strategies to Repair Barrier Dysfunction and Immune Dysregulation in Atopic Dermatitis
Synopsis
- Dual inhibition of kallikrein‑5 and ‑7 offers a protease‑based mechanism that intersects barrier dysfunction, inflammation, and itch in AD
- Unlike standard Th2‑targeted biologics, targeting KLK5/7 represents an orthogonal pathway informed by Netherton syndrome genetics and human expression datasets ex vivo human explant data show rapid improvements in epidermal integrity, reduced keratinocyte proliferation, and restoration of barrier proteins such as desmoglein‑1
- A next‑generation bispecific antibody combining KLK5/7 inhibition with IL‑13 blockade is being advanced to enhance efficacy across barrier and inflammation axes
4:30 pm Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development?
Synopsis
- How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective?
- Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach is most appropriate? How can we best utilize both routes to ensure there is a treatment fit for everyone?
- How are both approaches evolving to better meet patient needs, from systemics tackling severe or widespread disease to topicals aiming for convenience, safety, or even disease modification?
- What are the key trade-offs between topical and systemic treatments in terms of patient adherence, cost, quality of life, and long-term disease control and how can trials be designed to reflect this?